Biosimilar Approval Pathways: ANVISA vs COFEPRIS Insights 2026
This article delves into the 2026 biosimilar approval pathways of ANVISA and COFEPRIS, focusing on their implications for monoclonal antibody therapies.
Quick Answer
This article delves into the 2026 biosimilar approval pathways of ANVISA and COFEPRIS, focusing on their implications for monoclonal antibody therapies.
Key Questions
- What is the ANVISA-COFEPRIS mutual recognition agreement?
- How do ANVISA and COFEPRIS biosimilar pathways differ?
- What are the requirements for biosimilar approval in Brazil?
- What impact will regulatory convergence have on Latin American biosimilar markets?
- Does COFEPRIS require clinical trials to be conducted in Mexico?
Brazil's ANVISA and Mexico's COFEPRIS signed a Memorandum of Understanding in 2025 to mutually recognize GMP certificates and regulatory decisions for biosimilars. This agreement streamlines approval pathways, reduces redundant assessments, and accelerates patient access to affordable biologics across Latin America's two largest pharmaceutical markets.
Contents10 sections
Key Takeaways
- Regulatory reliance: The 2025 ANVISA-COFEPRIS MoU enables mutual recognition of GMP certificates and regulatory approvals, reducing duplicate assessments for biosimilar manufacturers.
- Pathway comparison: ANVISA operates under RDC 55/2010 requiring comparability studies, while COFEPRIS follows NOM-257-SSA1-2014 with biocomparability requirements evaluated by CMN and SEPB.
- Market impact: Harmonization is expected to reduce approval timelines, lower development costs, and expand access to biosimilars for oncology and autoimmune conditions across Brazil and Mexico.
- Future expansion: The agreement may extend to other Latin American regulators through WHO-aligned frameworks and PANDRH harmonization initiatives.
What Is the ANVISA-COFEPRIS Mutual Recognition Agreement?
In August 2025, Brazil's Health Regulatory Agency (ANVISA) and Mexico's Federal Commission for Protection against Health Risks (COFEPRIS) signed a Memorandum of Understanding to strengthen regulatory cooperation. The agreement establishes mutual recognition mechanisms for Good Manufacturing Practice (GMP) certificates and regulatory decisions for pharmaceuticals, including biosimilars.
The MoU builds on prior initiatives recognizing each agency as a reference regulatory authority. It creates formal pathways for information exchange, joint inspections, and reliance on each other's assessments. This approach reduces duplication of effort while maintaining safety standards.
The agreement specifically addresses the growing biosimilar market in Latin America. Both agencies have seen increasing submissions for monoclonal antibody biosimilars used in oncology and autoimmune diseases. By aligning their assessment processes, ANVISA and COFEPRIS aim to accelerate patient access while ensuring quality standards.
How Do ANVISA and COFEPRIS Biosimilar Pathways Compare?
ANVISA and COFEPRIS have both established biosimilar regulatory frameworks based on WHO guidelines, but implementation differs in specific requirements and processes.
| Requirement | ANVISA (Brazil) | COFEPRIS (Mexico) |
|---|---|---|
| Primary regulation | RDC 55/2010 | NOM-257-SSA1-2014 |
| Evaluating committees | Internal technical units | CMN and SEPB |
| Reference product | Must be registered in Brazil | Must be registered in Mexico |
| Clinical study requirements | Comparability studies required | May require local studies |
| Extrapolation permitted | Yes, if comparability demonstrated | Case-by-case evaluation |
| GMP certification | ANVISA GMP required | COFEPRIS GMP required |
ANVISA's Comparability Pathway
ANVISA's RDC 55/2010 establishes a comparability pathway requiring demonstration of similarity to a reference biologic in quality, safety, and efficacy. The regulation mandates comprehensive analytical studies comparing the biosimilar's physicochemical and biological properties to the reference product.
Non-clinical studies must demonstrate comparable pharmacokinetic and pharmacodynamic profiles. Clinical comparability trials are required to confirm no meaningful differences in safety or efficacy. ANVISA permits extrapolation to additional indications if the mechanism of action is the same and comparability is established for the tested indication.
COFEPRIS's Biocomparability Framework
COFEPRIS operates under NOM-257-SSA1-2014, which establishes requirements for biotechnological medicines including biosimilars. The Comité de Moléculas Nuevas (CMN) and Subcomité de Evaluación de Productos Biotecnológicos (SEPB) evaluate biocomparability studies.
Mexico's framework requires direct comparison with a reference biotechnological medicine registered in Mexico. Clinical studies may need to be conducted in Mexico depending on the Secretaría de Salud's determination based on CMN and SEPB recommendations. COFEPRIS also references NOM-177-SSA1-2013 for interchangeability requirements.
What Are the Requirements for Biosimilar Approval in Brazil?
ANVISA requires a stepwise comparability exercise demonstrating that the biosimilar matches the reference product. The process begins with extensive analytical characterization using state-of-the-art techniques.
Quality comparisons must cover physicochemical properties, biological activity, purity, and impurities. The biosimilar must match the reference in dosage form, strength, and route of administration. Stability studies must demonstrate comparable shelf-life.
Non-clinical studies include in vitro functional assays and, when necessary, in vivo studies. Clinical comparability trials must demonstrate equivalent efficacy and comparable safety and immunogenicity profiles. The reference product must have complete registration dossiers with ANVISA.
Does COFEPRIS Require Local Clinical Trials?
Mexico's approach to clinical data requirements varies by product. According to Diario Oficial documentation, COFEPRIS may require clinical studies to be conducted in Mexico based on recommendations from the CMN and SEPB.
The determination considers factors including the product's complexity, therapeutic indication, and whether ethnic or regional factors may affect safety or efficacy. Requirements for in vitro, preclinical, and clinical studies are tailored to each product and must align with the reference product's characteristics.
COFEPRIS has issued Regulatory Certainty Strategies to provide clarity on biosimilar requirements. These documents emphasize comprehensive frameworks to ensure safety and efficacy while streamlining evaluation processes.
What Impact Will Regulatory Convergence Have on Markets?
The ANVISA-COFEPRIS agreement is expected to reshape biosimilar development in Latin America. Manufacturers can leverage approvals from either agency to support applications in the other market, reducing regulatory burden and accelerating timelines.
For the biosimilar market, this convergence means:
- Reduced time-to-market for products approved by either agency
- Lower development costs through elimination of duplicate studies
- Increased competition as barriers to entry decrease
- Improved patient access to more affordable biologic therapies
The mutual recognition framework particularly benefits oncology biosimilars, where both Brazil and Mexico represent significant markets. Monoclonal antibodies for cancer treatment have been priority products for both agencies.
How Does This Align With Global Harmonization Efforts?
The ANVISA-COFEPRIS MoU supports broader regional harmonization through the Pan American Network for Drug Regulatory Harmonization (PANDRH). PANDRH's Biotechnological Products Working Group has been developing harmonized biosimilar guidelines for Latin America.
Both agencies have adopted WHO guidelines as foundational principles. The WHO Guidelines on Evaluation of Biosimilars emphasize reliance on nonclinical and clinical data from licensed originator products. These apply to well-characterized biologicals like recombinant proteins, excluding vaccines and plasma-derived products.
Regional harmonization remains incomplete. Countries including Argentina, Chile, Colombia, and Peru have adopted varying biosimilar frameworks. The ANVISA-COFEPRIS agreement may serve as a model for expanding mutual recognition to other major Latin American markets.
Frequently Asked Questions
What is the ANVISA-COFEPRIS mutual recognition agreement?
The 2025 Memorandum of Understanding between Brazil's ANVISA and Mexico's COFEPRIS enables mutual recognition of Good Manufacturing Practice (GMP) certificates and regulatory decisions for pharmaceuticals and biosimilars, reducing duplicate assessments and accelerating market access across Latin America.
How do ANVISA and COFEPRIS biosimilar pathways differ?
ANVISA follows RDC 55/2010 requiring comparability studies in quality, safety, and efficacy against a Brazilian-registered reference product. COFEPRIS uses NOM-257-SSA1-2014, which mandates biocomparability studies evaluated by the Comité de Moléculas Nuevas (CMN) and may require local clinical studies depending on the product.
What are the requirements for biosimilar approval in Brazil?
ANVISA requires analytical, non-clinical, and clinical comparability studies demonstrating no detectable differences from the reference product in quality, safety, and efficacy. The reference product must be registered in Brazil. Extrapolation to additional indications is possible if comparability is established.
What impact will regulatory convergence have on Latin American biosimilar markets?
Regulatory convergence through ANVISA-COFEPRIS cooperation is expected to reduce approval timelines, lower development costs for manufacturers, increase competition, and improve patient access to more affordable biologic therapies across Brazil, Mexico, and potentially other Latin American markets.
Does COFEPRIS require clinical trials to be conducted in Mexico?
COFEPRIS may require clinical studies to be conducted in Mexico depending on the determination by the Secretaría de Salud, based on opinions from the Comité de Moléculas Nuevas (CMN) and Subcomité de Evaluación de Productos Biotecnológicos (SEPB). Requirements vary by product.
Primary Sources
- ANVISA. "ANVISA fortalece cooperação regulatória com a COFEPRIS." Agência Nacional de Vigilância Sanitária, August 2025. https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2025/anvisa-fortalece-cooperacao-regulatoria-com-a-cofepris
- Brazil Ministry of Development, Industry and Trade. "Brasil e México fortalecem cooperação em saúde com mecanismos de confiança regulatória." August 2025. https://www.gov.br/mdic/pt-br/assuntos/noticias/2025/agosto/brasil-e-mexico-fortalecem-cooperacao-em-saude-com-mecanismos-de-confianca-regulatoria
- ANVISA. "Resolução da Diretoria Colegiada - RDC N° 55, de 16 de dezembro de 2010." https://bvsms.saude.gov.br/bvs/saudelegis/anvisa/2010/rdc0055_16_12_2010.pdf
- Secretaría de Salud, México. "NORMA Oficial Mexicana NOM-257-SSA1-2014." Diario Oficial de la Federación, December 11, 2014. https://dof.gob.mx/nota_detalle.php?codigo=5375517
- Secretaría de Salud, México. NOM-177-SSA1-2013. https://sidof.segob.gob.mx/notas/docFuente/5314833
- World Health Organization. "Guidelines on evaluation of similar biotherapeutic products (SBPs)." WHO Technical Report Series 977, 2022. https://www.who.int/publications/m/item/guidelines-on-evaluation-of-biosimilars
- COFEPRIS. "Estrategia de Certidumbre Regulatoria para Biosimilares." February 2024. https://www.gob.mx/cms/uploads/attachment/file/903867/Estrat_Cert_Regul_Biosimilares_b_080224.pdf
- Diario Oficial de la Federación, México. December 12, 2016. https://diariooficial.gob.mx/nota_detalle.php?codigo=5465061
Related coverage
This article follows our editorial standards. Report a correction via editorial contact.
